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Abstract
Flavonoid metal complexes commonly exhibit an improvement of biological activity 
compared to the parent ligands. This chapter is focused on the antioxidant and anticanc-
cer properties of flavonoid metal complexes, in correlation with their binding ability to 
vital macromolecules such as nucleic acids and serum proteins. Perspectives for an ade-
quate formulation of these complexes were also discussed.
Keywords: flavonoids, metal complexes, anticancer properties, nucleic acid binding, 
protein binding, formulation
1. Introduction
The urgency to overcome the biophysical and biomedical drawbacks of current chemothera-
peutic treatments led the scientists to consider flavonoid metal complexes as viable options 
in cancer therapy. Both in vitro and in vivo studies report that flavonoids and their metal ion 
complexes exert pleiotropic effects on tumor promotion and progression.
Our work is an attempt to help the design of novel flavonoid‐metal ion complexes with 
improved pharmacological activity and a broader range of antitumor mechanisms of action. 
In this chapter, we have analyzed relevant data available in literature on the antitumor activ-
ity of the flavonoid‐metal ion complexes, regarding their cellular targets, their role in cancer 
cell death, growth and proliferation, and structure‐activity analysis.
A novel metal‐based compound with antitumor activity and promising clinical efficacy should 
meet the following criteria: (1) possess good intrinsic properties, molecular stability, allowing 
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the drug to arrive intact at the target cells; (2) exert efficient interaction with transport proteins 
in blood and membranes; (3) show good DNA‐binding properties; (4) have selective activity 
against cancerous cells over normal cells; and (5) preferably have activity against tumor cells that 
are resistant to cisplatin and derivatives. These aspects will be discussed in the following pages.
2. Flavonoids: general information, main classes, and chelating properties
Flavonoids (from the Latin “flavus,” yellow) are secondary plant metabolites naturally occur-
ring in seeds, fruit skin, peel, and bark of plants [1]. Flavonoids are important components of 
the human diet, the major sources of flavonoids being apples, red fruits, onions, citrus fruits, 
nuts, and beverages such as tea, beer, and wine [2]. Although they are not considered nutri-
ents, due to the variety of pharmacological activities in the mammalian body, flavonoids are 
more correctly referred to as “nutraceuticals” [3].
These compounds possess a common flavane (2‐phenyl‐benzo‐γ‐piran) nucleus, consisting 
of an aromatic A‐ring fused to a heterocyclic C‐ring, attached through a single carbon‐carbon 
bond to a benzene B‐ring (Figure 1).
According to the oxidation degree of the C‐ring, the hydroxylation pattern of the nucleus, 
and the C3 substituent, the flavonoids can be categorized into seven subclasses: flavones, fla-
vonols, flavanones, flavanols (catechins), flavanonols, isoflavones, anthocyanins, and antho-
cyanidins [4–6]. Thus, the total number of polyphenolic compounds exceeds 4000. In all these 
subclasses, rings B and C are linked at C2, with the sole exception of the isoflavones (linked 
at C3). Many flavonoids occur naturally as glycosides; the carbohydrate substituents include 
D‐glucose, L‐rhamnose, glucorhamnose, galactose, and arabinose [7]. Table 1 lists the sub-
classes of flavonoids, and a set of representatives, to which we will refer to in this chapter.
Flavonoids possess three possible metal‐chelating sites that can bind metal ions: (i) the 3‐
hydroxy‐4‐ketone groups in the C‐ring, (ii) the 5‐hydroxy group in the A‐ring and 4‐car-
bonyl group in the C–ring, and (iii) 3’,4’‐dihydroxy groups, located on the B‐ring (Figure 2). 
Figure 1. Basic flavonoid structure.
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Flavonoid subclass General structure Representatives
Flavones Chrysin: 5=7=OH
Apigenin: 5=7=4’=OH Luteolin: 5=7=3’=4’=OH 
Diosmetin: 5=7=3’=OH, 4’=OCH3 Diosmin: Diosmetin‐7‐rutinoside
Flavonols Fisetin:7=3’=4’=OH Kaempferol: 5=7=4’=OH 
Quercetin: 5=7=3’=4’=OH Morin: 5=7=2’=4’=OH 
Myricetin: 5=7=3’=4’=5’=OH Galangin: 3=5=7=OH 
Rutin: Quercetin‐3‐rutinoside
Flavanones Naringenin: 5=7=4’=OH Hesperetin : 
5=7=3’=OH, 4’=OCH3 Naringin: Naringenin‐7‐
neohesperidoside Hesperidin: Hesperitin‐7‐
rutinoside Dio
Flavanols Catechin (2*R, 3*S): 5=7=3’=4’=OH Epicatechin 
(2*R, 3*R): 5=7=3’=4’=OH Epigallocatechin 
(2*R, 3*R): 5=7=3’=4’=5’=OH Epicatechin 
gallate (2*R, 3*R): 5=7=3’=4’=OH, 3‐gallic 
acid ester Epigallocatechin gallate (2*R, 3*R): 
5=7=3’=4’=5’=OH, 3‐gallic acid ester
Flavanonols Taxifolin (2*R, 3*R): 5=7=3’=4’=OH
Isoflavones Daidzein : 7=4’=OH Genistein: 5=7=4’=OH
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Cornard and Merlin [8] have reported that in acidic conditions, the 3‐hydroxy‐4‐ketone or the 
5‐hydroxy‐4‐keto groups of quercetin (Q) are involved in coordination, whereas in alkaline 
milieu, the second chelating site, 3’,4’‐dihydroxy group, located on the B‐ring, is also involved.
3. Antioxidant and prooxidant activity of flavonoids and their metal 
complexes
Flavonoids have been reported to possess various biological effects: anticarcinogenic [9–11], 
antiviral [12], anti‐inflammatory, immune stimulation [13, 14], antiallergic [15], and reducing 
the risk of cardiovascular disease [16–18].
Many of these beneficial health effects, including anticancer activity, arise from the antioxidant 
properties of these polyphenolic compounds [19], which are based on the following mechanisms:
(1) Direct radical scavenging: the flavonoid molecules are oxidized by free radicals (R●) re-
sulting in more stable, less reactive radicals [20]:
  FlOH + R ● → FlO ● + RH (1)
Flavonoid subclass General structure Representatives
Anthocyanidins, 
anthocyanins
Anthocyanidins Pelargonidin: 5=7=4’=OH 
Cyanidin: 5=7=3’=4’=OH Delphinidin: 
5=7=3’=4’=5’=OH Malvidin: 5=7=4’=OH, 
3’=5’=OCH Anthocyanins Cyanidin 3‐glucoside 
Cyanidin 3‐galactoside Cyanidin 3‐rutinoside 
Malvidin 3‐glucoside
Table 1. Main flavonoid [21] subclasses.
Figure 2. Typical chelation sites in forming the flavonoid complexes [2].
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where R● refers to either reactive oxygen species, ROS (hydroxyl, superoxide, peroxyl, alkyl 
peroxyl), or reactive nitrogen species, RNS (nitric oxide, peroxynitrite).
(2) Chelation of metal ions; the property of flavonoids to form chelates can be considered 
from two points of view:
• flavonoids bind metal ions like Fe(II), Fe(III), and Cu(II), thus preventing free radical gen-
eration in Fenton reactions:
  M n+ +  H 2 O 2  →  M (n+1)+ +  OH − + OH● (2)
• flavonoids form metal complexes that are generally more powerful antioxidants than the 
free ligands.
(3) Inhibition of various enzymes that are responsible for ROS/RNS formation (xanthine oxi-
dase, reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase).
(4) Upregulation of enzymatic and non‐enzymatic systems involved in the elimination and 
detoxification processes of oxidant species, such as reduced glutathione (GSH), GSH per-
oxidase, superoxide dismutase, and so on.
(5) Regeneration of the antioxidant species such as ascorbate and α‐tocopherol by electron 
transfer reactions [5].
Many studies have correlated the antioxidant activity of flavonoids with the following struc-
tural features (Figure 3):
1. ortho-dihydroxy substitution in the ring B;
2. the presence of a 2,3 double bond and of a 4-oxo function;
3. a 3‐hydroxy‐4‐keto and/or 5‐hydroxy‐4‐keto conformation [21].
Figure 3. Main structural features required for antioxidant activity of flavonoids.
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Among these main structural properties, it was observed that the antioxidant activity 
increases with the number of hydroxyl substituents and that the aglycones are more potent 
antioxidants than their corresponding glycosides [22].
Apart from the antioxidant activity, flavonoids can also exhibit prooxidant activity. This 
behavior is associated with the low one‐electron reduction potentials; some of them may 
autoxidize slowly under neutral conditions and faster in alkaline media, generating ROS 
[23]. Another mechanism of prooxidant activity is correlated with their ability to reduce Cu2+ 
and Fe3+, thus generating Fe2+ and Cu+ which in turn reduces hydrogen peroxide to hydroxyl 
radicals [24]. Prooxidant activity is thought to be directly proportional to the total number of 
hydroxyl groups [25], especially in the B‐ring [26], and the concentration of the flavonoid [27].
Commonly, the prooxidant activity of flavonoids has been associated with various toxic effects, 
but it is also possible for it to generate beneficial properties. For example, the apoptotic and 
bactericidal activity of epigallocatechin gallate is based on its ability to reduce O2 to yield H2O2 [28]. Likewise, the capacity of flavonoids to stimulate the activity of the detoxifying enzymes 
is a major mechanism for the chemopreventive properties of flavonoids, thus protecting the 
organism against mutagens and carcinogens [29].
A great number of metal complexes of flavonoid derivatives have been obtained, in order to 
improve the antioxidant activity of the parent flavonoid (Table 2).
Complex Molar ratio 
metaion:ligand
Effect on the flavonoid antioxidant activity Ref.
Flavonoid subclass: flavones
VO(II)‐luteolin 1:2 Increase [30]
Ge(IV)‐chrysin 1:1 Increase [31]
VO(II)‐chrysin 1:2 Increase [32], [33]
Ce(IV)‐chrysin 1:2 Increase [34]
VO(II)‐diosmin 1:1 Increase the scavenging activity only for 
ROO●, not for O2●−, DPHH●, OH●
[35]
Flavonoid subclass: flavonols
Mg(II)‐quercetin 1:1 Increase [36]
Al(III)‐quercetin 2:1 Increase [37]
Ge(IV)‐quercetin 2:1 ? [38]
Sn(II)‐quercetin Not determined Slightly decrease [39]
Fe(II)‐quercetin 1:2 Increase [40]
Co(II)‐quercetin 2:1 Increase [41]
Cu(II)‐quercetin 1:1 Increase [42]
Cu(II)‐quercetin 2:1 Increase [43]
Cd(II)‐quercetin 1:1 Decrease [44]
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Complex Molar ratio 
metaion:ligand
Effect on the flavonoid antioxidant activity Ref.
M(II)‐quercetin M = Mn, Co, Ni, Cu, Zn 1:2 Increase [45]
M(II)/(III)‐quercetin M(II) = Fe, Cu, Zn 
M(III) = Al
2:1 Increase [46]
Ln(III)‐quercetin Ln = La, Nd, Eu, Gd, 
Tb, Dy, Tm, Y
1:3 Increase [47]
VO(II)‐morin 1:2 Increase the scavenging activity for OH● and 
O2
− Decrease scavenging activity for ROO●.
[48]
Cr(III)‐morin 1:2 Increase [49]
Cu(II)‐morin 1:1 Increase [50]
M(II)/(III)‐galangin M(II) = Fe, Cu, Zn 
M(III) = Al
1:1 Increase [46]
Sn(II)‐rutin 1:2 Decrease [51]
Sn(II)‐rutin 3:2 Decrease [52]
Cr(III)‐rutin 2:1 Slightly increase [53]
Cr(III)‐rutin 3:1 Increase [54]
VO(II)‐rutin 1:2 Increase [55]
Ni(II)‐rutin 1:2 Increase [56]
Cu(II)‐rutin 1:1 Increase [57]
Zn(II)‐rutin 2:1 Increase [58]
Flavonoid subclass: flavanones
Cu(II)‐naringenin‐phenanthroline 1:1:1 Increase [59]
M(II)‐naringenin M=Cu, Zn, Ni 1:2 Increase [60]
Ce(IV)‐naringenin 1:2 Increase [34]
Cu(II)‐hesperetin‐phenanthroline 1:1:1 Increase [59]
Cu(II)‐naringin 1:1 Increase [61]
VO(II)‐hesperidin 1:1 Increase [62]
Flavonoid subclass: flavanols
M(II)/(III)‐catechin M(II) = Fe, Cu, Zn 
M(III) = Al
1:1 Increase [46]
Al(III)‐catechin 1:1 Decrease [37]
Flavonoid subclass: isoflavones
Cu(II)‐genistein Fe(III)‐genistein Cu(II)‐
biochanin A Fe(III)‐biochanin A
1:2 Increase for Cu(II) Prooxidant activity for 
Fe(III)
[63]
Ce(IV)‐daidzein 2:1 Increase [34]
Table 2. Metal complexes of flavonoids investigated for their antioxidant activity.
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By analyzing the data from Table 2 and the scientific literature, some observations appear to 
be relevant:
• most metal complexes behave as more powerful antioxidants compared to the parent 
flavonoids;
• the higher antioxidant activity of the metal complexes was generally explained by acquisi-
tion of an additional radical‐scavenging metal center by the complexes, probably a super-
oxide‐dismutase‐mimicking center;
• in some cases, the metal (e.g., Sn2+, Cd2+) complexes show lower antioxidant activity than 
the parent flavonoids; the lower antioxidant activity can be explained by the fact that chela-
tion of these metal ions significantly changes the chemical properties of the flavonoid, or 
might increase the oxidation potentials relative to those of the free flavonoid;
• some metal complexes, especially those of Fe(III) ions, display prooxidant activity.
4. Anticancer activity of flavonoids metal complexes
The cytotoxic activity of flavonoids involves the inhibition of several molecular targets and 
pathways: DNA topoisomerases I and II [64], cyclin‐dependent kinases CDK2 and/or CDK1 
[65], androgen receptor signaling [66], actin polymerization [67, 68], activation of p53, and inhi-
bition of NFkB pathways [69]. Flavonoids activate the caspase-mediated signal transduction 
pathways, consecutively stimulating the tumor‐suppressor protein p53, which  consequently 
triggers cell apoptosis [69].
In many cases, the antitumor activity of the flavonoid metal complexes has been reported to 
be greater than that of the free corresponding flavonoids [47]. This may be mediated through 
the regulation of important cell‐cycle events, alterations in the DNA structure, prooxidant 
effects, or interactions with the phospholipid bilayer. Flavonoid metal complexes have been 
reported to be active against gastric cancer cells, human hepatocellular carcinoma cells [70], 
human cervical carcinoma cells [71], leukemia cells [61], human colon adenocarcinoma cells, 
human hepatoma cells, and osteoblast cancer cells [62]. A very important and promising 
feature displayed by these complexes is that a number of them have proven to be selective 
toward cancerous cells over normal cells [72]. Table 3 contains a selection of metal complexes 
of flavonoids which have shown antitumoral activity.
As it has been shown in Table 5, complexes contain diverse structures, derived from the variety 
of flavonoids and metal ions used in the drug design. Regarding the flavonoid structures in 
metal complexes, the type of the substituents on either ring in the ligand structure, whether 
electron‐withdrawing or electron donating, seems to have minor importance. However, their 
position appears to be crucial for the cytotoxic activity. Ortho-substitution of the B-ring appears 
to be unfavorable, while meta‐ and para-substitution augments the anticancer activity. This may 
be due to a structural effect, as the B (phenyl)‐ring is more twisted in the ortho-substituted com-
pounds than in the meta- and para‐derivatives, which may increase the interaction with biological 
targets. The purpose of combining these ligands with metal centers is to obtain anticancer agents 
with extended mechanistic range, facilitating single‐molecule multi‐target anticancer therapy.
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Complex Comments Ref.
4’‐Methoxy‐5,7‐dihydroxy‐
isoflavone Complexes with 
Mn(II)*, Cu(II), Zn(II), Co(II), 
Ni(II) Metal ion:isoflavone 
molar ratio 1:2
Cell lines: HeLa (cervical cancer), MDA‐MB‐435 (breast carcinoma), 
SW620 (colon carcinoma), HepG2 (liver cancer), A549 (non‐small‐cell 
lung carcinoma). *was most efficient, especially on line SW620 (IC50 < cisplatin). Flow cytometry analysis showed that * acts in the G2/M 
phase of the cell cycle, causing early apoptosis.
[73]
Rutin complex with Zn(II) 
(Znrut) Metal ion:isoflavone 
molar ratio 1:1
KG1 (leukemia): IC50 = 91.4 µM; K562 (leukemia): IC50 = 173.2 µM; Jurkat (leukemia): IC50 = 150.2 µM; RPMI8226 (multiple myeloma): IC50 = 196.6 µM; B16F10 (melanoma): IC50 = 160.7 µM; SK‐Mel‐28 (melanoma): 
IC50 = 194.0 µM. In the Ehrlich ascites carcinoma model, Znrut exerts modulating effect of mitochondrial membrane potential and expression 
of genes involved in cell cycle control, apoptosis and angiogenesis.
[74]
Diosmin complex with 
oxovanadyl (IV) [VO(dios)
(OH)3]Na5·6H2O (VOdios)
A549: dios‐ IC50 > 100 µM, at 100 µM, VOdios decreases cell viability by 31%; T47D (breast tumor): dios exerts no antiproliferative 
effect, VOdios – IC50 = 23.3 µM; SKBR3 (breast adenocarcinoma): 
dios – IC50 > 100 µM, VOdios – IC50 = 46.4 µM; MDAMB231 (breast adenocarcinoma): dios – IC50 = 70 µM, VOdios – IC50 = 11.6 µM. An antiproliferative non‐apoptotic mechanism, caspase 3/7 and oxidative 
stress independent, has been proposed.
[35]
Luteolin complex with 
oxovanadyl (IV) [VO(lut)
(H2O)2]Na·3H2O (VOlut)
MDAMB231: IC50 = 17 µM (lut: IC50 = 88.3 µM); A549: IC50 = 60.5 µM (lut: IC50 = 66.3 µM); Both Lut and VOlut generate ROS and mitotic 
arrest; VOlute causes nuclear and cytoplasmic membrane damage.
[75]
Naringenin complex 
with oxovanadyl (IV) 
[VO(nar)2]·2H2O (VOnar)
A549: nar shows no antiproliferative effect, VOnar: IC50 > 100 µM (at 100‐µM cell viability decreases by 35%); SKBR3: nar shows no 
antiproliferative effect, VOnar: IC50 = 73 µM; MDAMB231: nar: IC50 > 100 µM (at 100‐µM cell viability decreases by 30%), VOnar: IC50 = 20 µM. VOnar antiproliferative effect was accompanied by ROS generation, cell 
membrane damage and DNA degradation, cell cycle arrest, caspase 3/7 
activation, and mitochondrial membrane potential decrease.
[76]
Chrysin complex 
with oxovanadyl (IV) 
[VO(chrys)2EtOH]2 (VOchrys)
MC3T3E1 (normal osteoblast cell line), UMR106 (osteosarcoma). Both 
the ligand and the complex exert similar inhibitory effect on normal 
cells and cancer cells (60% inhibition at 100 µM for osteosarcoma 
cells). Complexation does not improve the antitumor properties of 
the free flavonoid. In vitro and in vivo studies were performed on 3D 
human osteosarcoma and xenograft osteosarcoma mice models. The 
pharmacological results show that VOchrys had an inhibitory effect 
on cell viability, affecting the shape and volume of the spheroids and 
suppressed MG‐63 tumor growth in the mice models without toxic and 
side effects.
[32, 33, 77]
Quercetin (Quer) complex 
with oxovanadyl (IV) 
[VO(Quer)2EtOH]n (VOQuer)
MC3T3E1 (normal osteoblast cell line), UMR106 (osteosarcoma). 
The complexation of quercetin does not improve its potential 
anticarcinogenic properties. The complex was more cytotoxic toward 
normal osteoblasts. VOQuer interacts with two markers of osteoblastic 
differentiation; it stimulates type I collagen production and inhibits 
bovine ALP‐specific activity; QuerVO stimulated the phosphorylation 
of ERKs in a dose‐response manner, showing that the mitogenic effect 
of the complex in osteoblasts may involve the ERK pathways. VOQuer 
shows potential for promoting osteoblast differentiation.
[78]
cis‐[Pt(PPh3)2(3‐Hfl)]Cl (1) 
cis‐[Pt(PPh3)2(etga)] (2) PPh = triphenylphosphine, 
3‐Hfl = 3‐hydroxyflavone 
monoanion, etga = etilgalat 
dianion
U87 (glioblastoma): IC50(µM) values: 3‐Hfl: 27.5 ± 2.3; (1): 26.3 ± 2.1; etga: 97.7 ± 2.6; (2): 123.7 ± 3.8; cisplatin: 1.76 ± 0.22; MCF‐7 (breast 
tumor): IC50(µM) values: 3‐Hfl: 108.1 ± 3.5; (1): 55.5 ± 1.7; etga: > 200; (2): >200; cisplatin: 14 ± 3.
[79]
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Complex Comments Ref.
Ru(II) cis‐dichlorobis(3‐
imino‐2‐methoxy‐flavanone) 
(1) Ru(II) cis‐dichlorobis(3‐
imino‐2‐ethoxy‐flavanone) 
(2) Ru(II) cis‐dichloro(3‐
nitrozoflavone)(3‐
hydroxyiminoflavanone)(3)
A549: IC50(µM) values: cisplatin: 3.8 ± 0.8; (1): ∼100; (2): 5.3 ± 0.4; (3): 3.8 ± 0.3; A2780 (ovarian cancer): IC50(µM) values: cisplatin: 0.2 ± 0.1; (1): 39.6 ± 3; (2): 2.5 ± 0.2; (3): 1.8 ± 0.1; A2780cis (cisplatin‐resistant subline): 
IC50(µM) values: cisplatin: 16.8 ± 1.5; (1): 62.5 ± 16; (2): 4.6 ± 0.2; (3): 1.5 ± 0.04; Toledo (diffuse large B‐cell lymphoma): IC50(µM) values: cisplatin: 0.5 ± 0.07; (1): 13.9 ± 1.2; (2): 0.5 ± 0.1; (3): 0.6 ± 0.04; Toledo‐cis (cisplatin‐
resistant subline): IC50(µM) values: cisplatin: 8.3 ± 0.6; (1): 56.6 ± 2.8; 
(2): 2.9 ± 0.2; (3): 2.8 ± 0.1. Lymphocytes: IC50 (µM) values: cisplatin: 0.2 ± 0.1; (1): 19.4 ± 3; (2): 3.4 ± 0.3; (3): 1.6 ± 0.2. The complexes had minor 
effects on hemostasis or on the red blood cell lysis in vitro, at cytotoxic 
concentrations and are therefore unlikely to cause hematologic 
disorders in vivo.
[80]
Ru(II) complex with 
η6-p‐cymene and 3‐
hydroxyflavone derivatives
CH1 (ovarian carcinoma), SW480 (colon carcinoma, A549 (non‐small‐cell 
lung carcinoma), 5637 (human urinary bladder), LCLC‐103H (human 
large‐cell lung), DAN‐G (human pancreatic carcinoma cell lines). The IC50 values were in the low micromolar range. The chemosensitive CH1 
cell line was very sensitive to the complexes with IC50 values < 7.9 µM; for SW480, the IC50 values: 3.4–26 µM. The lowest cytotoxic potency was found for A549 (IC50: 8.6–51 µM). Some of the complexes have an influence on the cell cycle distribution; at concentrations around the 
IC50 values of the complexes, an increase in the cell fraction in G0/G1 phase was observed. Most of the complexes strongly inhibit CDK2, 
inhibit topoisomerase IIα to a greater extent than the corresponding 
free ligands (the activity on topo‐IIα correlates with the cytotoxic effect 
of the complexes).
[81]
Quercetin complexes 
with Zn(II), Mn(II) 
[Zn(que)2(H2O)2] (1) [Mn(que)2(H2O)2] (2)
HepG2: IC50(µM) values: (que)2: 13.3 ± 1.0; (1): 5.46 ± 0.36; (2): 8.0 ± 0.3; SMMC‐7221 (hepatocarcinom): IC50(µM) values: (que)2: 13.3 ± 1.0; (1): 7.66 ± 0.30; (2): 8.0 ± 0.3; A549: IC50(µM) values: (que)2:13.3 ± 1.0; (1): 10.0 ± 0.45; (2): 8.0 ± 0.3. The antitumor activity of (2) may be 
partially attributed to the interaction with the GC‐rich DNA sequences 
and to DNA protein‐binding interactions. These processes lead to 
downregulation of survivin gene expression, caspase activation, and 
induction of apoptosis. HepG2 cells had undergone morphological 
changes typical of apoptosis, characterized by nuclear shrinkage, 
chromatin condensation, and fragmentation subsequent to exposure to 
complex (1). The cytotoxic effect is partially attributed to intercalation 
between DNA base pairs.
[82, 83]
Chrysin (1), apigenin (2), 
genistein (3) homoleptic 
Cu(II) Complexes (4)–(6), 
respectively
518A2 (melanoma): IC50(µM) values: (1): > 50; (2): > 50; (3) > 50; (4): 10.9 ± 1.6; (5): 13.2 ± 1.1; (6): 10.9 ± 1.4; HCT‐116 (colon carcinoma): IC50(µM) values: (1): > 50; (2): > 50; (3) > 50; (4): 14.8 ± 2.7; (5): 15.8 ± 2.5; (6): 10.4 
± 1.6; KB‐V1/Vbl (cervix carcinoma): IC50(µM) values: (1): 12.5 ± 2.1; (2): 20.6 ± 1.7; (3) 28.8 ± 3.0; (4): 4.6 ± 0.5; (5): 8.0 ± 1.2; (6): 6.7 ± 0.5; MCF‐7/
Topo (breast carcinoma): IC50(µM) values: (1): 28.2 ± 6.1; (2): 31.2 ± 0.9; 
(3) 37.0 ± 3.0; (4): 7.8 ± 1.5; (5): 11.8 ± 0.7; (6): 8.5 ± 1.4; The cytotoxic 
activity of the complexes was correlated with an arrest of the cell 
cycle of 518A2 cells at the G2/M transition. The complexes gave better 
results than the free flavonoids in decreasing the migration propensity 
of 518A2 cells in wound‐healing assays. The antimetastatic effects 
of complex (6) derive from the remodeling of the actin cytoskeleton 
and the increase in cadherin‐catenin complex formation, factors that 
favor cell‐cell adhesion. Complex (6) decreased the expression and 
secretion of the metastasis‐related matrix metalloproteinases MMP‐2 
and MMP‐9. Thus, the coordination of apigenin and genistein to Cu(II) 
enhances the antitumoral properties of the free flavonoids and expands 
their mechanistic range.
[84]
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It should be kept in mind that with the failure of ASA404/vadimezan (Antisoma/Novartis) 
in a phase III trial for advanced non‐small‐cell line cancer when given in combination with 
carboplatin and taxol [86], there are no more benzopyran‐4‐one derivatives strong candidates 
for anticancer drugs. The research regarding the antitumor properties of flavonoid metal 
complexes offers promising results and these should be further improved in order for the 
complexes to enter clinical trials.
5. Interactions of flavonoids metal complexes with proteins
Protein binding can influence the blood levels and the pharmacokinetic behavior of a drug 
and possibly its pharmacologic and toxicologic profiles. Human serum albumin (HSA) is 
quantitatively ∼55% of total serum proteins. Analyses of the crystal structure of the protein 
indicate that the main binding sites in HSA are located in the hydrophobic cavities of subdo-
mains II and III of site A. These binding sites are known as Sudlow I and II, respectively. The 
remaining single tryptophan in HSA structure is located within the site’s Sudlow I (Trp‐214) 
[87]. Serum albumin (SA) is involved in blood transport for many compounds and metal ions. 
The interactions of a drug with SA play a major role in drug efficacy. Flavonoids and their 
metal complexes interact in the microenvironment surrounding the tryptophan residue of SA.
Transferrin (Tf) is a monomeric glycoprotein, containing two main metal ion binding sites: 
the N‐terminal lobe and the C‐terminal lobe, similar in structure, each binding one Fe(III) ion. 
It has been found that iron‐binding sites in the serum Tf are only saturated to an extent of 39% 
of Fe(III), meaning that the free lobes can bind other metal ions [88]. Cancer cells, as active and 
rapidly proliferating cells, express high levels of transferrin receptors. Consequently, transfer-
rin has been explored as a potential drug carrier for targeted delivery into tumor cells [89].
Moreover, human topoisomerase II‐α (topo II‐α) is currently a target for anticancer chemo-
therapy. Topo II‐α is involved in DNA transcription, replication, and chromosome segrega-
tion. Although these biological functions are vital for insuring genomic integrity, the ability 
to inhibit topo II‐α and generate enzyme‐mediated DNA damage in cancer cells is an effective 
strategy in antitumor therapy [90]. Electrostatic forces, hydrogen bonds, and van der Waals 
interactions are involved in the interactions of flavonoid metal complexes and proteins [72].
Flavonoids and their metal complexes bind bovine serum albumin (BSA) or human (HSA), in 
vitro, with different affinities (Table 4).
Complex Comments Ref.
Chiral L/D‐valine (val) 
quercetin (Q) organotin(IV) 
complexes [(CH3)2Sn(Q)(val)] 1L/D [(C6H5)2Sn(Q)(val)] 2L/D
HeLa: IC50 (µg mL−1) values: < 10; MCF‐7: IC50 (µg mL−1) values: < 10; 
HepG2: IC50 (µg mL−1) values: 1L: 34.6; 2L: < 10; MIA‐Pa‐Ca‐2 (pancreas cancer): IC50 (µg mL−1) values: < 10; The mechanistic activity of the complexes appears to involve interaction with topoisomerase I and 
DNA.
[85]
ALP: alkaline phosphatase; ERK: extracellular‐regulated kinase; CDK2: cyclin A protein kinase.
Table 3. Metal complexes of flavonoids with antitumor activity.
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Complex Comments Ref.
Diosmin‐oxovanadyl (IV) complex 
[VO(dios)(OH)3] Na5·6H2O (VOdios)
Diosmin and VOdios interactions with BSA follow a 
static mechanism, a ratio of 1: 1 compound: protein; the 
interaction is enabled via hydrogen bonds and van der 
Waals forces. At 298 K: K
b dios
 = 1.84 ± 0.32 × 104 M−1 K
b VOdios
 = 
55.3 ± 0.07 × 105 M−1
[35]
Luteolin‐ oxovanadyl (IV) complex 
[VO(lut)(H2O)2] Na·3H2O (VOlut)
Luteolin interacts with the microenvironment around 
tryptophan in BSA, by electrostatic forces; the complex 
interacts with the protein through hydrogen bonds and van 
der Waals forces. The interaction takes place in a ratio of 1: 
1 compound: protein through a static mechanism. At 298 K: 
K
b lut
 = 65.10 ± 0.90 × 106 M−1 K
b VOdios
 = 79.43 ± 0.56 × 106 M−1
[75]
Naringenin‐oxovanadyl (IV) complex 
[VO(nar)2]·2H2O (VOnar)
The interaction takes place in a ratio of 1:1 
compound:protein through a static mechanism. 
Complexation lowered the binding affinity to BSA of 
naringenin, probably due to steric hindrance. At 298 K: K
b nar
 
= 10.20 ± 0.30 × 104 M−1 K
b VOnar
 = 0.31 ± 0.01 × 104 M−1
[76]
Quercetin and morin and their 
sulfonic derivatives-oxovanadyl 
(IV) complexes VO(que)2 VO(mor)2 VO(queS)2 VO(morS)2
In the systems with apo‐human transferrin (apo‐HTF) and 
albumin (HSA), VO(que)2 and VO(QueS)2 are stable, while VO (mor)2 and VO(morS)2 undergo displacement reactions, when the species (VO)
x
(HSA) and (VO)(apo‐HTF)/
(VO)2(apo‐HTF) and VO‐apo‐HTF‐morS and morS‐VO‐HAS are formed. The complexes interact strongly with the 
proteins by the formation of hydrogen bonds with polar 
groups on the protein surface. VO(que)2/VO(QueS)2 does not interact with hemoglobin, while VO(mor)2/VO(morS) forms adducts with hemoglobin (Hb).
[91]
Baicalein‐Al(III) complex (ALBC) The results of the competitive binding and molecular-
docking studies indicate that BC binds to HSA at site 
I (subdomain IIA), while ALBC binds mainly at site II 
(subdomain IIIA). BC binding had a greater influence than 
ALBC on the secondary structure of the protein. At 297 K: 
K
b BC
 = 1.73 × 105 M−1 Kb ALBC = 1.67 × 105 M−1
[92]
Dihydromyricetin Mn(II), Cu(II) and 
Zn(II) complexes MnDMY CuDMY 
ZnDMY
DMY‐BSA interaction is achieved by van der Waals forces 
and hydrogen bonds, while complexes bind through 
hydrophobic and hydrogen‐bonding forces (conclusions 
based on thermodynamic values for parameters). At 300 K: 
Kb DMY = 1.30 × 105 M−1 Kb MnDMY = 2.13 × 105 M−1 Kb CuDMY = 2.95 × 105 M−1 Kb ZnDMY = 7.76 × 104 M−1
[93]
Morin‐La(III) complex (La‐Mo) La‐mo‐HSA interaction was studied by means of 
spectrofluorometry and circular dichroism. It has been 
found that La‐mo is an efficient interaction with HSA 
hydrogen bonding and van der Waals forces. The 
thermodynamic parameters (ΔG, ΔH, ΔS) that characterize 
the interaction had negative values, implying that the 
binding is thermodynamically favorable and the degree of 
reversibility is modest. Circular dichroism spectra show a 
reduction in the α‐helix‐type structures from 60.0 to 56.9% 
and an increase in the β‐chain‐type structures from 6.0 to 
7.1% in HSA. Molecular‐docking studies show that La‐mo 
competes with warfarin site Sudlow I of subdomain II in 
HSA structure. At 299 K: Kb La‐Mo = 1.5752 ± 0.007 × 105 M−1
[94]
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6. Interactions of flavonoids metal complexes with nucleic acids
The ability of small molecules to interact with DNA ranks among the most important mecha-
nisms of action enabling antitumor activity, since intercalation between adjacent base pairs 
inhibits DNA replication. Most of the flavonoids and their metal complexes show affinity 
toward nucleic acids. Flavonoids bind DNA as a result of electrostatic interactions, as is the 
case of quercetin [97] and morin [98 and references therein]. Their complexes, on the other 
hand, are bulkier, and display more diversified mechanisms of interaction with DNA, includ-
ing “major” or “minor groove” binding and/or intercalation. Due to their structural planarity, 
flavonoid complexes are prone to act as intercalators [99]. Moreover, the emergence of electro-
static interactions between the metal cation and anionic phosphate groups of DNA structure 
stabilizes the adducts formed between the complexes and DNA. It is considered that the DNA 
base pairs remove the flavonoid molecules in the metal complex, since the binding affinity 
between the negatively charged phosphate groups and the positively charged metal ions is 
stronger than that between the flavonoid molecule and the metal center [100, 101]. In most 
cases, active compounds possess quasi‐planar structures, with a medium‐sized planar area 
and hydrophobic character [82]. A selection of the metal complexes of flavonoids that interact 
with DNA is presented in Table 5.
Another aspect regarding DNA interaction refers to the complexes’ cleavage activity. This 
property can benefit their antitumor activity, but can also cause oxidative DNA damage (and 
consequently cell death) in normal cells [22]. Therefore, efforts toward increasing the com-
plexes’ selectivity against cancer cells are of prior importance.
The development of electrochemical DNA biosensors has been of high interest in this field, 
since metal flavonoid complexes show promising results in DNA recognition. Flavonoid com-
plex‐based biosensors can be useful in several domains, such as transducing DNA hybridiza-
tion, drug design, and diagnosis [102, 103, 105].
Complex Comments Ref.
Ru(II)‐η6-p-cymene complex 
  
R=CH3, F or Cl
The complex interacts with topoisomerase II‐α and the 
interaction depends on the substituent located at the para-
position of the phenyl ring. The complex where R=Cl is 
the most potent topoisomerase inhibitor. The complexes 
showed better activity than the ligands.
[95]
Quercetin-CuII‐Sn2IV heterobimetallic 
complex
The complex is a potent inhibitor of topoisomerase I at 30 
µM.
[96]
K
b
: binding constant; K
i
: inhibition constant.
Table 4. Selection of flavonoid metal complexes‐protein interactions studies.
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Complex Comments Ref.
Fe(II)‐quercetin complex Fe(quer)2 The interaction of the complex with DNA occurs in a moderate intercalative manner. Fe(quer)2 shows cleavage activity on plasmid DNA (pBR322) under physiological 
conditions, via oxidative pathway.
[40]
Ni(II)‐rutin (R) complex metal:ligand 
molar ratio 1:2 (NiR)
The interaction of NiR with DNA was studied using 
fluorescence spectra and agarose gel electrophoresis. The 
complex can intercalate moderately between DNA base 
pairs and shows significant, dose‐dependent cleavage 
activity on pBR322 plasmid DNA from the SC form to the 
NC form.
[52]
Fe(III) chlorobis(flavonolato) 
(methanol) complex metal:ligand 
molar ratio 1:2 Fe(III)‐(3hf)
The complex shows cleavage activity toward CT‐DNA via an 
oxidative mechanism with higher efficacy in the presence of 
reducing agents (ascorbate/hydrogen peroxide).
[101]
Cd(II)‐morin complex Cd(mor)2 The interaction with salmon sperm dsDNA was studied by means of electrochemical methods. Cd(mor)2 can intercalate into the double‐helix DNA; according to the Hill model for 
cooperative binding, the equilibrium dissociation constant and 
the binding stoichiometry were calculated to be K = 2.5 × 10−5 M 
and m = 1.761, respectively.
[102]
Co(II)‐morin complex Co(mor)2 Competitive experiments, viscosity, and electrochemical studies indicate that the complex binds to DNA via a weak 
partial intercalation. K
b
 = 2 × 103 M−1 at 20°C.
[103]
Morin (1) Cu(II)‐morin complex (2) 
Morin‐β‐CD (3)
Intercalation was proposed as the mode of binding of the 
ligand, the complex with salmon sperm dsDNA via cyclic and 
square wave voltammetry, UV‐vis spectroscopy techniques. 
K
b
 values: (1): 1.58, (2): 2.29, (3): 3.20 × 105 M−1 at 298 K. Other 
studies indicate that morin interacts with DNA in a non‐
intercalative manner [98].
[104]
Cu(II)‐rutin (R) complex Cu2R3 The interaction of Cu2R3 with salmon sperm dsDNA was studied by means of cyclic voltammetry and fluorescence 
spectroscopy. The complex interacts with DNA via 
intercalation and nonspecific electrostatic interaction. 
Cu2R3 was used for the construction of an electrochemical DNA biosensor for DNA hybridization detection, showing 
relatively good sensitivity and selectivity.
[105]
Cu(II)‐hesperetin complex K
b
 = 1.5 × 106 M−1 The UV‐vis, fluorescence and CD spectral 
measurements revealed that both the complex and the ligand 
interact with CT‐DNA via intercalation. The binding affinity 
of the complex is stronger than that of free ligand.
[59, 70]
Cu(II)‐quercetin complex 
metal:ligand molar ratio 1:2
By means of UV‐vis spectrophotometry, cyclic voltammetry, 
and synchronous fluorescence spectroscopy, an intercalative 
binding mode was proposed. K
b
 = 1.82 ± 0.2 × 105 M−1 
The equilibrium constant of the exchange process in the 
intercalation reaction was found to be approximately 5 
× 10−1; 35% of the bound complex was not involved in 
intercalation.
[106]
Tb(III)/Eu(III)‐quercetin system A sensitive method for the determination of CT‐DNA is 
proposed based on the quenching effect of DNA on the RLS 
intensity of Tb(III)/Eu(III)‐quercetin system.
[100]
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Regarding the interaction of the complexes with RNA, a few studies have been cited in the 
literature. La(III)‐quercetin complex enhances binding to plant viral satellite dsRNA [109]. Both 
quercetin and the complex interact with dsDNA, dsRNA, and ssRNA. The affinities of La(III)‐
quercetin for dsDNA and dsRNA were significantly higher compared to the free ligand, reveal-
ing significant impact of La(III) in binding to polynucleotides, most likely due to the electrostatic 
interactions between La(III) and the phosphate groups surrounding binding sites. Similar 
results were observed for interactions of the La(III)‐quercetin complex with ssRNA [110].
Complex Comments Ref.
Chiral L/D‐valine (val) quercetin 
(Q) diorganotin(IV) complexes 
[(CH3)2Sn(Q)(val)] 1L/D [(C6H5)2Sn(Q)(val)] 2L/D
UV‐vis, fluorescence titrations, thermal denaturation, and 
circular dichroism studies revealed the electrostatic mode of 
DNA binding of the complexes, although partial intercalation 
into the DNA helix and hydrophobic interactions cannot be 
excluded. K
b
 values (: 1L: 2.17 × 105 M−1; 1D: 1.00 × 104 M−1; 2L: 4.74 × 105 M−1; 2D: 1.40 × 104 M−1) revealed that the L‐enantiomers of 
exhibited exceptionally high-binding propensity as compared 
to their D‐enantiomers. 1L and 2L exhibit supercoiled DNA cleavage ability mediated by single strand breaks.
[85]
La(III)‐chrysin complex K
b chrysin
 = 1.29 × 106 M−1; K
b complex
 = 5.44 × 105 M−1 
Spectrophotometric methods and viscosity measurements 
indicated that La(III) complex and chrysin can both bind to 
DNA by intercalation modes.
[107]
Eu(III)‐quercetin complex Eu(quer)3 The CT‐DNA interactions were studied using cyclic 
voltammetry and double potential step chronocoulometry at 
glass carbon electrode for the surface method. Quercetin binds 
to DNA mainly by electrostatic interaction and the complex 
binds to DNA by means of intercalation and electrostatic 
forces. For the dsDNA‐modified GCE systems, the following 
parameters were obtained: Γ
s quercetin
 = 2.28 ± 0.2 × 10−10 mol/cm3 
n
quercetin
 = 1.2 Γs Eu(quer)3 = 1.65 ± 0.2 × 10−10 mol/cm3 n Eu(quer)3 = 1.8
[97]
Mn(II)‐quercetin complex 
metal:ligand molar ratio 1:2
UV/VIS, fluorescence spectroscopy, and viscosity 
measurements were carried out. The results indicate that the 
complex binds preferentially in the GC‐rich regions via an 
intercalative mode.
[83]
Zn(II)‐quercetin complex 
metal:ligand molar ratio 1:2
The complex promotes plasmid DNA cleavage, producing 
single‐ and double‐DNA strand breaks. The amount of 
conversion of the SC form to the NC form depends on the 
concentration of the complex and the duration of incubation 
with DNA. The rate of conversion of SC to NC is 1.68 × 10−4 s−1 
at pH 7.2 (100 µM complex).
[108]
CuII- Sn 
2
 
IV
 ‐quercetin ZnII- Sn 
2
 
IV
 
-quercetin
The heterobimetallic-type complexes form electrostatic 
interactions with DNA (between SnIV and the phosphate 
groups) and covalent bond between the metal center and 
nitrogenous bases. The complex CuII- Sn 
2
 
IV
 -quercetin exhibits 
nuclease and SOD‐mimetic activity.
[96]
ds: double‐stranded; CT‐DNA: calf thymus DNA; RLS: resonance light scattering; Γ
s
: saturation coverage value; GC: 
guanine‐cytosine; SC: supercoiled; NC: nicked circular form.
Table 5. Selection of flavonoid metal complexes‐DNA interaction studies.
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Undisputedly, there is a consistent amount of experimental evidence regarding the interac-
tion of flavonoids and their metal complexes with nucleic acids. However, some details with 
respect to the binding sites in the DNA structure need further investigations. There appears 
that the complexes possess higher affinity toward GC‐rich sequences in DNA [111], but this 
assumption needs to be backed up by more data.
7. Perspectives in the formulation of flavonoids metal complexes
In order to enhance the water solubility and to control the release of flavonoids metal com-
plexes, many efforts have been focused on the preparation of cyclodextrin complexes, or of 
novel micro‐ and nano‐carriers, such as liposomes and organic compounds‐inorganic par-
ticles hybrid materials (HMs). In the following subchapter, the most important systems devel-
oped for the inclusion of flavonoids metal complexes with antioxidant or antitumor activity 
will be reviewed, as well as the systems that include flavonoids with antitumor activity based 
on the complexation process between flavonoid and metal ions.
7.1. Liposomal systems
Flavonoids’ ability to penetrate into the hydrophobic regions of lipid bilayers in biological mem-
branes is a key factor to prevent peroxidation of unsaturated double bonds. In this regard, the 
lipophilicity of flavonoids is essential for an adequate penetration. According to Tweedy’s chela-
tion theory, the polarity of the metal ion is reduced, as a consequence of chelation, mainly because 
of the partial sharing of its positive charge with the ligand’s donor groups and possible elec-
tron delocalization over the entire ring. Consequently, the lipophilic character of the chelates 
increases, favoring their permeation through the lipid layers of biological membranes [112]. For 
two complexes of quercetin and taxifolin with Fe(II), it was assumed that the oxygen charges are 
generally decreases, while the main negative charge is localized on the iron atom. Thus, after che-
lating the metal ion, the polarity of flavonoid molecules generally decreased, while the iron atom 
becomes the most polar and hence hydrophilic part of the molecule. Overall, the lipophilicity of 
the complexes is considerably larger than that of the corresponding free flavonoids [113, 114].
On the other side, the hydrophobicity of flavonoids chelates dramatically reduces the water 
solubility, which restricts their medical applications. Integration of these complexes into lipo-
somes may increase their bioavailability and improve the therapeutic effect.
The interaction study of quercetin‐iron complexes with dimyristoylphosphatidylcholine 
(DMPC) or palmitoyl‐oleoyl phosphatidylethanolamine (POPE) multilamellar liposomes 
revealed that, during preparation, quercetin should be added first to the suspension of lipo-
somes [115]. It was presumed that quercetin can increase the permeability of lipid bilayers to 
iron cations, showing ionophore activity toward iron cations.
7.2. Cyclodextrins
The inclusion into cyclodextrins is a convenient alternative to solve the problems related to 
the low solubility of hydrophobic drugs, such as flavonoid complexes. Inclusion of Cu(II) and 
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Cr(III) complexes of flavonoids morin, quercetin, and 6‐hydroxyflavone into β‐cyclodextrin 
led to an enhancement of aqueous solubility [116]. The anticancer activity of metal‐flavonoid 
complexes was evaluated in terms of dsDNA binding in the environment of beta‐cyclodex-
trin, and it was revealed that DNA could bind Cu‐flavonoid‐βCD through intercalation and 
Cr‐flavonoid‐βCD via an electrostatic‐binding mode.
7.3. Organic/inorganic hybrid nanosystems
Based on the property of flavonoids to reduce metal ions such as Ag(I) and Au(III), some 
hybrid systems of flavone/metal nanoparticles have been developed. It was suggested that 
flavanones can be adsorbed on the surface of metallic nanoparticles through the interaction of 
the metals with the carbonyl groups or π electrons in the flavonoid structures [117].
The effect of 3‐hydroxyflavone (3‐HF) in a silver nanoparticles (SNPs) complex on the cell via-
bility and on the cell morphology of L929 mouse fibroblast cells was studied in vitro. The contri-
bution of the carrier protein BSA to 3‐HF properties has also been investigated. Determination 
of the cell viability using MTT assay revealed that 3‐HF in BSA/SNPs systems presented no 
cytotoxic effect in L929 mouse fibroblast cells at any of the tested concentrations [118].
In order to enhance the interaction efficacy with biomacromolecules and therefore increase 
its therapeutic potential, morin was conjugated with citrate‐coated Au nanoparticles (M‐C‐
AuNPs). Interactions of M‐C‐AuNPs and C‐AuNPs with BSA were studied in order to com-
pare the efficiency of M‐C‐AuNPs and C‐AuNPs in biological systems. It was found that the 
binding affinity toward BSA of M‐C‐AuNPs is significantly higher than that of C‐AuNPs’, 
indicating that M‐C‐AuNPs might show better BSA interaction efficiency, better biocompat-
ibility, and chemical stability than C‐AuNPs [119].
Taking into account the potential biomedical applications, for example, targeted drug deliv-
ery, several flavonoids with antioxidant and antitumor activities have been conjugated with 
magnetic nanoparticles, mainly Fe3O4. Flavonoid molecules can bind to Fe3O4 via the hydroxyl substituents in their deprotonated form. Most of the biomedical applications of magnetic 
nanoparticles require surface modification for drug loading or anchoring linkers in support of 
sustained drug release. Surface functionalization with PEG (polyethylene glycol), PVP (poly-
vinylpyrrolidone), PVA (polyvinyl acetate), peptides, carbohydrates, proteins, and so on facili-
tates the drug loading and controlled release, and also controls the stability of the system [120].
Quercetin‐conjugated superparamagnetic Fe3O4 nanoparticles were investigated for the in 
vitro cytotoxic activity on breast cancer cell lines. The MTT assay revealed that the dextran‐
coated Fe3O4 nanoparticles did not exhibit notable toxicity against MCF7 cells, whereas the cytotoxicity of quercetin‐conjugated Fe3O4 nanoparticles increased significantly in compar-ison with the free quercetin [120]. The results sustain that the quercetin‐conjugated Fe3O4 
nanoparticles are promising anticancer agents for targeted drug delivery.
A drug delivery methodology was proposed to study a new quercetin release system in the 
form of magnetite‐quercetin‐copolymer (MQC), as perspective of targeting specific organs 
within the body. The quercetin‐magnetite nanoparticles (Fe3O4) system was incorporated into a triblock copolymer of ethylene oxide and oxyphenylethylene, as a model of drug carrier 
system for anticancer agents [121].
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Furthermore, quercetin loading on mesoporous carriers was performed in order to enable the 
sustained delivery of the bioactive compound. Mesoporous nanosized silicas are widely used 
as carriers for drug delivery. However, the appropriate chemical surface modification of the 
mesoporous matrix is essential, taking into account that the silanol groups of the silica surface 
do not possess sufficient selectivity to adsorb drug molecules with different functionalities 
[122]. Quercetin was loaded on the pure silica and Zn‐modified mesoporous MCM‐41 and 
SBA‐16 supports, and the formation of complexes between quercetin and pure siliceous or 
Zn‐modified MCM‐41 and SBA‐16 mesoporous silica was determined. Quercetin has a higher 
binding affinity for the Zn2+ cation than to the silanol groups. Therefore, the release of querce-
tin is easier from the silicate samples containing only superficial silanol groups than from the 
Zn‐modified samples. The obtained mesoporous delivery systems with Zn‐quercetin com-
plex showed promising results for further use in dermal formulations [123].
Natural zeolite of the clinoptilolite type (CT, particle size of up to 200 µm) and its modi-
fied forms with different concentrations (0.06–5%) of the pharmaceutically active compounds 
quercetin and quercetin dihydrate (QD) have been investigated for their anticancer activity. 
Carcinoma cell lines Jurkat, CEM, HeLa, MCF7, A549, and MDA were treated with various 
amounts of natural clinoptilolite and their modified forms CTQ and CTQD. Incorporation of 
the flavonoids quercetin and quercetin dihydrate with antiproliferative activity had no syn-
ergic effect on the zeolite cytotoxicity, but the protective effect of cancer cells. The tumor cell 
lines studied after the application of modified zeolite CTQ or CTQD had lower antiprolifera-
tive activity in comparison with the natural zeolite of the clinoptilolite‐type CT. The modified 
zeolite CTQD had greater antiproliferative effects than modified zeolite CTQ [124].
8. Conclusions and future perspectives
There is an impressive number of studies with reference to the antitumor activity of fla-
vonoids. However, even though the metal complexation of flavonoids generally results in 
enhanced antitumor activity, the number of studies regarding flavonoid metal complexes is 
much smaller. Moreover, none of the flavonoid metal complexes that have shown great anti-
tumor activity has been included in clinical trials so far. This may happen due to the chal-
lenges implied by the study of the multiple possible mechanisms induced by the presence of 
the metal ion. Stability of the complexes in physiological context may also raise some impor-
tant issues. Therefore, further studies are required to understand their mechanisms of action 
and their biotransformation in the human body.
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